

ASX/MEDIA RELEASE

ASX: BMI 02 March 2009

STRONG RESULT FOR BMDI TUTA 2008-09 HALF-YEAR REPORT

- Revenue up 343% to \$4.11m.
 - Gross profit up 339% to \$1.87m.
 - EBITDA of \$123,307[†], up \$740,274.
 - Operating profit of \$13,081[†], up \$657,570.
 - On track to deliver profit in FY 2008-09.
-

Sydney, Australia: **BMDI TUTA Limited (ASX: BMI)** today announced its half year report for the six months ended 31 December 2008.

Key Points – Financial

- Consolidated revenue was \$4.11m for the period, up 343% compared with revenue of \$928,800 for the previous comparable period (PCP) reflecting the additional revenue contribution from the TUTA Healthcare acquisition.
- Gross profit increased by 339% to \$1.87m from \$426,300 in the PCP, a reflection of the more favourable product mix generated through further rationalisation of the TUTA and BMDi ranges, and ongoing efforts to drive cost savings across the Company's global supply chain.
- EBITDA for the period, adjusted for one-off acquisition and restructure costs, showed a profit of \$123,307, a turnaround of \$740,274.
- The unadjusted operating loss recorded for the period was \$272,379, down 60% on the PCP loss of \$644,500. When adjusted for one-off costs associated with the acquisition and subsequent restructure of the TUTA Healthcare business, an operating profit of \$13,081 was recorded.

[†] Excluding abnormal items including one-off restructure and acquisition costs.



TOWARD A SAFER WAY.

Corporate Highlights

The Company completed in the period the integration and restructure of the TUTA Healthcare business acquired in March 2008. The resulting boost to revenue, expanded customer base and product offering, together with the significant operational cost savings which were able to be made means that the Company is well on track to deliver its maiden profit in the current financial year.

BMDI TUTA has defined five core areas in which to build its competitive edge: intravenous and medical systems, safety collection and injection, blood banking, surgical products and anaesthesia.

The capability and capacity of BMDI TUTA to deliver on large local and international supply contracts has been further enhanced by the expansion of its manufacturing base in late 2008. Other key achievements of the past six months have been the re-building of the Company's Quality System to meet stringent TGA and CE Mark standards and development and launch of new products and brands.

A number of changes at Board level occurred during the period. Non-executive director, Thomas Mann replaced as Chairman, Keith Cadell who sadly passed away in June 2008. In November the Company announced the resignation of Dr. Mal Eutick and the appointment of Mr. Ian Mitchell to the Board. Mr. Mitchell, who is a practicing solicitor with BA, Dip Law qualifications from Sydney University, has extensive experience in commercial law and directing public companies.

Outlook

BMDI TUTA is now well positioned to grow market share within its focus areas and to further develop its OEM sales to major international medical companies for outsourced manufacturing.

As indicated at the Company's AGM held on 28 November, the outlook for 2009 includes the following objectives: export development to further leverage the Company's core brands; and to expand the portfolio in line with the strategic plan particularly in areas such as medical systems, blood banking and veterinary; and by pursuing its successful acquisition strategy.

For more information contact:

Gary Lewis
Managing Director, BMDI TUTA
Ph: +61 2 9466 5300

BMDI TUTA Limited is a medical technology company engaged in the manufacture, distribution and sale of a broad range of medical devices used by healthcare facilities and critical care services in global markets. BMI's strategy is to provide products that improve clinical and community safety, by delivering a range of safety-engineered medical devices with a focus on five clinical therapy areas: Intravenous and medical systems, safety injection and collection products, blood banking, surgical products and anesthesia.